Delving into the Latest Updates on 122-0551 with Synapse

Overview

Basic Info

Drug Type

Peptide Hormone

Synonyms

122-0551

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Plaque psoriasis

Originator Organization

Therapeutics, Inc.

Active Organization-

Inactive Organization

Therapeutics, Inc.

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of 122-0551 versus the corresponding Vehicle in subjects with stable plaque psoriasis after twice daily dosing for 14 consecutive days.

Start Date01 May 2012

Sponsor / Collaborator

Therapeutics, Inc.

NCT01698333

/ CompletedPhase 2

An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment

Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is designed to determine the adrenal effects of the investigational formulation of 122-0551 and characterize the steady state pharmacokinetics of the formulation.

Start Date01 Apr 2012

Sponsor / Collaborator

Therapeutics, Inc.

100 Clinical Results associated with 122-0551

Login to view more data

100 Translational Medicine associated with 122-0551

Login to view more data

100 Patents (Medical) associated with 122-0551

Login to view more data

100 Deals associated with 122-0551

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plaque psoriasis	Phase 2	United States	Therapeutics, Inc.	01 Apr 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01700985 (CTgov)	Phase 2	Plaque psoriasis	44	122-0551 (122-0551)	xtapjqbmee = mjataivole rgrkthzgnt (rnlsdurmxf, ifnsacxvfd - myufazwnri) View more	-	25 Oct 2018
NCT01700985 (CTgov)	Phase 2	Plaque psoriasis	44	Vehicle (Vehicle)	xtapjqbmee = rfigrxqgba rgrkthzgnt (rnlsdurmxf, rkevkfzmvy - emdkepqiwc) View more	-	25 Oct 2018
NCT01698333 (CTgov)	Phase 2	Plaque psoriasis	25	122-0551	zjgzfqdcfd = fhzxdsudjb zqpvvnhyio (liroigqbov, protejzrwp - rtcqsfvflc) View more	-	26 Sep 2018

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data